A review of autophagy mechanism of statins in the potential therapy of Alzheimer's disease

• Published in: Journal of integrative neuroscience 2022-03, Vol.21 (2), p.46-46
• Main Authors: Liu, Lu, Dai, Wen-Zhuo, Zhu, Xi-Chen, Ma, Tao
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - metabolism; alzheimer's disease; Amyloid beta-Peptides - metabolism; amyloid-β; Autophagy; autophagy flux; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; mevalonate pathway; Signal Transduction; statin; tau protein
• ISSN: 0219-6352
• DOI: 10.31083/j.jin2102046

Alzheimer's disease (AD) is a neurodegeneration csharacterized by amyloid-β (Aβ) deposition and abnormally phosphorylated Tau protein aggregation. Autophagy, as an important cellular metabolic activity, is closely related to the production, secretion and clearance of Aβ peptide and Tau phosphorylation level. Therefore, autophagy may become a potential target for AD treatment. A large number of molecules are involved in the mammalian target of rapamycin (mTOR)-dependent or mTOR-independent pathway of autophagy. More and more evidences show that statins can intervene autophagy by regulating the activity or expression level of autophagy-related proteins and genes. On the one hand, statins can induce autophagy through Sirtuin1 (SIRT1), P21, nuclear P53 and adenylate activated protein kinase (AMPK). On the other hand, statins inhibit the mevalonate metabolism pathway, thereby interfering with the prenylation of small GTPases, leading to autophagy dysfunction. Statins can also reduce the levels of LAMP2 and dynein, destroying autophagy. In this review, we focused on the role of autophagy in AD and the autophagy mechanism of statins in the potential treatment of AD.